Atezolizumab + Bevacizumab

DRUG2 trials

Sponsors

Hospices Civils de Lyon, Michael Dill

Conditions

Advanced Gastric CarcinomaGastric AdenocarcinomaHCC - Hepatocellular CarcinomaImmunotherapyMetastatic AdenocarcinomaMetastatic Gastric Cancer

Phase 2

Personalized Targeted IMMUNOtherapy-based Regimens in Recurrent GASTric Adenocarcinoma (IMMUNOGAST)

Hospices Civils de LyonAdvanced Gastric Carcinoma, Gastric Adenocarcinoma, Metastatic Adenocarcinoma +1

Start: 2021-03-19End: 2023-10-26Target: 60Updated: 2021-03-29

Fecal Microbiota Transfer in Liver Cancer to Overcome Resistance to Atezolizumab/Bevacizumab (FLORA)

RecruitingNCT05690048

Michael DillHCC - Hepatocellular Carcinoma, Immunotherapy

Start: 2025-07-16End: 2028-03-31Target: 48Updated: 2025-08-06

Related Papers

Protocol: Faecal microbiota transfer in liver cancer to overcome resistance to atezolizumab/bevacizumab – a multicentre, randomised, placebo-controlled, double-blind phase II trial (the FLORA trial)

BMJ Open2025-09-012 citations